


Sitaxsentan

Cat. No.:	HY-76520
CAS No.:	184036-34-8
Molecular Formula:	C ₁₈ H ₁₅ ClN ₂ O ₆ S ₂
Molecular Weight:	454.9
Target:	Endothelin Receptor
Pathway:	GPCR/G Protein
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

Sitaxsentan (IPI 1040; TBC-11251) is a selective endothelin A (ETA) receptor antagonist. Antihypertensive. Sitaxsentan is used in treatment of chronic heart failure. IC50 value: Target: ETA receptor

CUSTOMER VALIDATION

- Biotechnol Bioeng. 2021 Sep 3.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Chin M, Levy RD, Yoshida EM, Byrne MF. Sitaxsentan-induced acute severe hepatitis treated with glucocorticoid therapy. *Can Respir J*. 2012 Jan-Feb;19(1):e1-2.
- [2]. Sandoval J, et al. STRIDE-4 investigators. Safety and efficacy of sitaxsentan 50 and 100 mg in patients with pulmonary arterial hypertension. *Pulm Pharmacol Ther*. 2012 Feb;25(1):33-9. Epub 2011 Nov 2.
- [3]. Safdar Z. Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension. *Vasc Health Risk Manag*. 2011;7:119-24. Epub 2011 Mar 2.
- [4]. Rondelet B, et al. Sildenafil added to sitaxsentan in overcirculation-induced pulmonary arterial hypertension. *Am J Physiol Heart Circ Physiol*. 2010 Oct;299(4):H1118-23. Epub 2010 Aug 6.
- [5]. Kaehler, et al. Successful treatment of portopulmonary hypertension with the selective endothelin receptor antagonist Sitaxentan. *Wien Klin Wochenschr*. 2011 Apr;123(7-8):248-52. Epub 2011 Mar 31.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA